ArticleBMC pharmacology & toxicology2025
Development and validation of a risk prediction model for meropenem-related thrombocytopenia in patients with pulmonary infection.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe prevalence of meropenem-related thrombocytopenia has risen in tandem with the growing utilization of meropenem in clinical settings. Consequently, we aimed to develop a risk prediction model for meropenem-related thrombocytopenia in patients with pulmonary infection and to enhance the safety for the clinical administration of meropenem.
methodsA retrospective case-control study was conducted to collect data. The training group consisted of patients who were treated with meropenem for pulmonary infection at a tertiary A hospital in Shiyan from January 2018 to December 2021. The external validation group was formed from patients at another tertiary A hospital from January 2019 to January 2020. Multivariable logistic regression analysis was employed to investigate the risk factors linked to meropenem-related thrombocytopenia. Subsequently, these factors were utilized to develop a nomogram for predicting meropenem-related thrombocytopenia. The Bootstrap method was conducted to internally validate the nomogram model. The discrimination, calibration, and clinical effectiveness of the model were assessed through the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).
resultsA total of 625 patients were included in the training group. Among them, 73 patients experienced meropenem-related thrombocytopenia. Multivariate logistic regression analysis revealed that hypertension, baseline platelet count, and combined with cephalosporins or penicillins were independent risk factors for meropenem-related thrombocytopenia in patients with pulmonary infection. A risk prediction model was developed based on these four factors. The model demonstrated an AUC (area under the ROC curve) of 0.774 (95%CI: 0.718 ~ 0.829), with a sensitivity of 0.685 and a specificity of 0.737. The optimal critical value was determined to be 0.137. Internal validation yielded an AUC of 0.761, while external validation resulted in an AUC of 0.750 (95%CI: 0.702 ~ 0.799). The calibration diagram indicated a high level of agreement between the predicting and actual probabilities. Furthermore, the DCA demonstrated that the model had significant clinical benefit and practical value.
conclusionA risk prediction model based on hypertension, baseline platelet count, combined with cephalosporins or penicillins could effectively predict the occurrence of meropenem-related thrombocytopenia in patients with pulmonary infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.